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Essentials 1 
 Correct length of treatment after an index unprovoked 2 
Venous Thromboembolism (VTE) is unknown. 3 
 Cost-utility analysis assessed at what predicted VTE risk it is 4 
worthwhile to restart therapy. 5 
 Results imply restarting therapy if a patient’s 1 year VTE risk 6 
is ≥17.5% may be cost-effective. 7 
 However, sensitivity analyses indicate large parameter 8 
uncertainty in base case results. 9 
 10 
Summary 11 
Background: Following at least three months of anticoagulation 12 
therapy after a first unprovoked Venous Thromboembolism (VTE), 13 
there is uncertainty about the duration of therapy. Further 14 
anticoagulation therapy reduces the risk of having a potentially fatal 15 
recurrent VTE but at the expense of a higher risk of bleeding which 16 
can also be fatal.  17 
Objective: An economic evaluation sought to estimate the long-term 18 
cost-effectiveness of using a decision rule for restarting 19 
anticoagulation therapy versus no extension of therapy in patients 20 
based on their risk of a further unprovoked VTE.  21 
Methods: A Markov patient-level simulation model was developed 22 
which adopted a lifetime time horizon with monthly time cycles and 23 
was from a UK National Health Service (NHS) /Personal Social 24 
Services (PSS) perspective. 25 
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Results: Base case model results suggest that treating patients with 1 
a predicted one year VTE risk of 17.5% or higher may be cost-2 
effective if decision makers are willing to pay up to £20,000 per 3 
Quality Adjusted Life Year (QALY) gained. However probabilistic 4 
sensitivity analysis show the model was highly sensitive to overall 5 
parameter uncertainty and warrants caution in selecting the optimal 6 
decision rule on cost-effectiveness grounds. Univariate sensitivity 7 
analyses indicate variables such as anticoagulation therapy disutility 8 
and mortality risks were very influential for driving model results.  9 
Conclusion: This represents the first economic model to consider the 10 
use of a decision rule for restarting therapy for unprovoked VTE 11 
patients. Better data are required to predict long-term bleeding risks 12 
on therapy in this patient group. 13 
  14 
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Introduction 1 
Venous Thromboembolism (VTE) is the development of a clot in the 2 
veins. The number of deaths from VTE in the UK each year is five 3 
times greater than deaths from breast cancer, AIDS, and road traffic 4 
incidents combined [1] and the cost of managing VTE was estimated 5 
at around £640 million to the UK National Health Service (NHS)[2]. 6 
While there are several risk factors that can provoke an initial VTE 7 
event (such as hormone intake, surgery, trauma, pregnancy and 8 
prolonged immobility), patients can suffer an initial VTE event 9 
without any known trigger (unprovoked).[3-5] Patients with an 10 
unprovoked VTE have a much higher risk of VTE recurrence than 11 
patients whose index VTE event has an identifiable cause.[6] The UK 12 
National Institute of Health and Care Excellence (NICE)[7] and the 13 
American College of Chest Physicians (ACCP) [8] recommend at least 14 
3 months anticoagulation therapy following a first unprovoked VTE 15 
event; after three months of anticoagulation therapy following a 16 
first unprovoked VTE event, there is clinical equipoise on whether to 17 
extend anticoagulation therapy.[9-11] Extending anticoagulation 18 
therapy reduces the risk of having a possible recurrent VTE fatality; 19 
but treatment increases the risk of bleeding which can be fatal. 20 
Balancing the benefit and harm of further treatment requires the 21 
identification of risk of recurrent VTE and an optimal threshold of 22 
VTE risk above which recommending anticoagulation therapy is 23 
beneficial.  24 
A previously developed prognostic model estimated an individual 25 
patient’s risk of a further unprovoked VTE without treatment.[12] A 26 
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decision rule was developed using this prognostic model to stratify 1 
patients treatment strategies based on a threshold of VTE 2 
recurrence risk (e.g. 5% VTE recurrence risk at 1 year post therapy). 3 
This study aims to evaluate the cost-effectiveness of a decision rule 4 
for restarting therapy in patients after a first unprovoked VTE. The 5 
prognostic model uses data from D-Dimer testing 30 days after 6 
cessation of anticoagulation, however this test is not currently part 7 
of routine practice. A systematic review did not uncover any 8 
economic evaluations using a decision rule in this patient group.[12]  9 
Methods 10 
Model population 11 
The patient population comprised adult individuals having already 12 
completed at least three months of anticoagulation therapy in 13 
response to their first unprovoked VTE. An initial VTE was defined as 14 
unprovoked where there was no history in the previous three 15 
months of any of the following risk factors: major surgery, lower 16 
limb trauma, use of combined oral contraceptive pill or hormone 17 
replacement therapy, pregnancy, significant immobility, or cancer. 18 
Patients entered the model having already had their D-Dimer level 19 
measured thirty days after stopping at least three months of 20 
anticoagulation therapy. Individual patients were generated from 21 
patient data (Recurrent VTE Collaborative database)[13] previously 22 
used to develop the prognostic model.  Each patient had 23 
characteristics created by randomly sampling the patient-level data 24 
by means of a uniform distribution. Patient characteristics 25 
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comprised age [mean: 61.7 years; standard deviation: 15.2], gender 1 
[61.8% Male], type of index VTE event (Distal Deep Vein Thrombosis 2 
(DVT)[9.2%], proximal DVT [58.5%], and Pulmonary Embolism 3 
(PE)[32.3%]) and post-anticoagulation D-Dimer level [mean: 4 
667.3µg/L; standard deviation: 751.3]. The individual’s risk of a 5 
recurrent VTE within 12 months was then determined by inputting 6 
their newly created characteristics into the prognostic model risk 7 
equation (Appendix Table I).[12] The risk distribution of the 8 
simulated patients is given in Appendix Table II. 9 
 10 
Model pathways and clinical events 11 
The economic model compared a strategy of no therapy (usual care) 12 
with a number of decision rule strategies, where therapy was 13 
restarted if the predicted annual risk of VTE recurrence was equal to 14 
or greater than the given threshold risk (Appendix Fig I). For 15 
pragmatic reasons, the arbitrary but clinically relevant thresholds 16 
were explored in the analyses:1%, 3%, 5%, 7.5% 10%, 12.5%, 15%, 17 
17.5%, 20%, 22.5%, 25% and a treat-all strategy was also included as 18 
a comparator. These specified VTE risks were used as different 19 
decision rule comparators (example patient predicted risks are given 20 
in Appendix Table III). No patients initially resumed anticoagulation 21 
therapy in the no decision rule comparator. The decision rule was 22 
applied at the starting point of the model only. Once the decision 23 
rule was applied, all the patients encountered the same potential 24 
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pathways in all strategies (Fig I), with their characteristics 1 
determining the probabilities of clinical events, costs and utilities.  2 
In one month, an individual had the probability of experiencing one 3 
clinical event: death from other causes, recurrent VTE (non-fatal 4 
distal or proximal DVT, fatal or non-fatal PE), fatal or non-fatal major 5 
bleeds (intracranial bleed, gastrointestinal bleed, and other major 6 
bleeds). A recurrent VTE carried a risk of Post-Thrombotic Syndrome 7 
(PTS). 8 
Other cause mortality was dependent on the current age and 9 
gender of the patient and was taken from UK life tables.[14] 10 
Recurrent VTE risk depended on a patient’s characteristics, time 11 
spent in the model, previous history of a recurrent VTE event taking 12 
place in the model, and treatment status. A recurrent VTE could be a 13 
PE, distal DVT, or proximal DVT. The recurrent VTE type was 14 
assumed to be affected by an individual’s initial VTE site. Once a 15 
patient suffered a recurrent VTE, they were put on anticoagulation 16 
therapy for life with therapy cessation only occurring with a later 17 
major bleeding event. VTE events were assumed to incur a one-off 18 
quality of life reduction, with a proportion of surviving patients 19 
assumed to suffer from severe PTS for life. 20 
The risk factors for a major bleed in the model were treatment 21 
status and an individual’s’ age if on treatment. Major bleeds were 22 
split into “gastrointestinal bleeds”, “intracranial bleeds” and “other 23 
major bleeds.” All major bleeding events had short-term costs and 24 
quality of life decrements. In addition, an intracranial bleed was 25 
Economic evaluation of restarting OAC therapy  
 
8 
 
assumed to be associated with ongoing costs and a permanent 1 
quality of life decrement along with a sustained increased lifetime 2 
risk of other cause mortality. For the “other major bleeds” category, 3 
it was agreed by clinical consensus that this heterogenous category 4 
of bleeds should have the same costs and quality of life decrement 5 
as a gastrointestinal bleed, for model simplification purposes. 6 
Any major bleeding event led to discontinuation of anticoagulation 7 
therapy. A recurrent VTE in a later cycle was assumed to restart 8 
therapy. It was assumed that there was no effect of anticoagulation 9 
therapy on VTE recurrence risk by thirty days post cessation of 10 
therapy.  11 
Model type 12 
A Markov patient-level simulation was developed in TreeAge 2014 13 
(TreeAge software, Williamstown, MA, USA) to estimate the cost-14 
effectiveness of using a decision rule for restarting anticoagulation 15 
therapy versus no anticoagulation therapy (usual care) in patients 16 
with a first unprovoked VTE event. A Markov model was deemed 17 
appropriate as it can represent a clinical situation where patients 18 
move between health states over a long period of time. A patient-19 
level simulation allows individual patients, each with a set of varying 20 
characteristics created from patient level data, to be assigned a risk 21 
of VTE recurrence. Patient characteristics and clinical events which 22 
affect subsequent risks were remembered in the model with tracker 23 
variables. The model was run with a large number of simulated 24 
patients (50,000) to account for inter-patient variability. 25 
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A time cycle of one month was selected to represent an assumption 1 
that this reflects a period in which a single clinical event might 2 
occur. Costs, utilities and probabilities were transformed into 3 
monthly equivalents as per the time cycle length. A half cycle 4 
correction was applied to costs and effects. The base-case cost-5 
utility analysis was undertaken from a UK National Health Service 6 
(NHS)/ Personal Social Services (PSS) perspective and considered a 7 
lifetime horizon.  8 
Clinical Parameters 9 
Parameter estimates and their sources are listed in Table I. The base 10 
case scenario used warfarin as the anticoagulation therapy. The risk 11 
of a patient’s first recurrent VTE off therapy was calculated using the 12 
prognostic model for up to three years post D-Dimer measurement 13 
(30 days after initial therapy cessation). Weak calibration statistics 14 
of the prognostic model after three years prompted the use of an 15 
annual constant risk for the first recurrent VTE event off therapy 16 
thereafter. [15] Annual risk of a further VTE event after a VTE 17 
recurrence was an average of values for patients with normal and 18 
elevated D-Dimer levels, on and off therapy respectively in the 19 
PREVENT trial.[16]  20 
Resource use and costs 21 
Costs of therapy and clinical events were included in the model 22 
(Table I). The cost of a D-Dimer test was incurred by the decision 23 
rule strategies as the D-Dimer information was needed to enact the 24 
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decision rules. All costs were updated to 2012/2013 prices using the 1 
Hospital and Community Health Services (HCHS) Index.[17]  2 
Quality of life 3 
Quality of life (utility) values were assumed to be age related as they 4 
enter the model using EuroQol–5 Dimensions (EQ-5D) UK normative 5 
values.[18] As patients aged in the model, their utility score changed 6 
to reflect their updated quality of life for their age. Utility values for 7 
clinical events and being on warfarin therapy (Table II) were 8 
multiplied by the age-specific utility to derive quality of life 9 
reductions for patients experiencing a clinical event and/or on 10 
warfarin therapy.  11 
Assessment of cost-effectiveness 12 
The sequential incremental analysis was designed to calculate the 13 
cost per quality-adjusted life year (QALY) gained for applying a 14 
decision rule versus the next most effective option, applying the 15 
rules of dominance and extended dominance. Cost-effectiveness 16 
was assessed in relation to the National Institute for Health and Care 17 
Excellence (NICE) lower threshold of £20,000 per QALY, where a 18 
value of £20,000/QALY is judged to be cost-effective.[19] Strategies 19 
were compared by increasing effectiveness and incremental cost-20 
effectiveness ratios (ICERs) were calculated from the difference in 21 
costs and effects between a decision rule strategy and the next best 22 
alternative. A strategy is said to be dominated if they were more 23 
expensive and less effective than a comparator. All costs and 24 
outcomes were discounted at the recommended 3.5%.[20] 25 
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Deterministic Sensitivity Analysis 1 
To test the robustness of base-case results, a number of 2 
deterministic sensitivity analyses were run to determine the impact 3 
of changing key parameters on results.  4 
 The model time horizon was restricted to 3 years 5 
corresponding to the length of time the VTE prognostic 6 
model is used.[12] 7 
 The utility of warfarin therapy was reduced from 0.997 to 8 
0.950 to assess how greater disutility associated with 9 
anticoagulant treatment affects results.  10 
 The probability of death from a PE was increased to 30% 11 
due to uncertainty amongst clinical experts on the true 12 
value.  13 
 The model entry was restricted to patients aged 60 and 14 
above, where risk of bleeding on therapy is higher.  15 
 Sub-group analyses were undertaken for index PE patients 16 
and index DVT patients, as the sub-group of PE patients 17 
were at higher risk of recurrence and mortality. 18 
 Sub-group analyses were undertaken for male and female 19 
patients respectively 20 
 The lag time in days for d-dimer was adjusted from 30 days 21 
to 20 and 40 days respectively which changed the risk 22 
profile of the patients. 23 
Probabilistic Sensitivity Analysis 24 
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Where available, data were input into the model as distributions to 1 
assess parameter uncertainty in the form of a probabilistic 2 
sensitivity analysis (PSA). The model was rerun with 10,000 3 
simulations for each trial of 1,000 simulated patients and the results 4 
expressed as cost-effectiveness planes and cost-effectiveness 5 
acceptability curves (CEACs). 6 
Results 7 
Base Case Results 8 
Under base-case assumptions, restarting warfarin therapy for 9 
patients with a predicted annual VTE recurrence risk of 25% gave 10 
the lowest cost per QALY of £1,983 (Table III). However, resuming 11 
anticoagulation therapy for patients with a predicted annual VTE 12 
recurrence risk of 17.5% yielded the highest number of QALYs while 13 
also being considered cost-effective with an ICER of £14,980/QALY 14 
gained.  15 
Probabilistic Sensitivity Analysis Results 16 
The PSA results demonstrate there is considerable uncertainty 17 
around the base case results. The cost-effectiveness planes 18 
(Appendix Fig II-VIII) show the large uncertainty in the QALY 19 
differences for all strategies. The majority of the cost-QALY 20 
difference values indicate all strategies to be more costly than 21 
treating no-one, but many of the points were in the north-west 22 
quadrant, where a strategy is more expensive and less effective 23 
compared to treat no-one (dominated). 24 
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The CEACs, which compared the most cost-effective base case 1 
option (17.5%) against several strategies (10%,12.5%,15%, 20%, 2 
22.5%, 25%), show that treating those with a one year VTE risk of 3 
17.5% has a 44.8-73.3% probability of being cost-effective at a 4 
willingness to pay threshold of £20,000 per QALY gained (Appendix 5 
Fig IX-XV). The results highlight substantial parameter uncertainty 6 
even if the calculated ICER point estimates for the base-case results 7 
appear to be cost-effective. 8 
Deterministic sensitivity analysis results 9 
Deterministic sensitivity scenario results are shown in Table IV. 10 
These illustrate that some variables were pivotal in changing the 11 
direction of model results. Assuming a greater disutility of being on 12 
warfarin therapy permits the 22.5% and 25% threshold decision rule 13 
to be cost-effective.  14 
Increasing the risk of death from PE had improved the cost-15 
effectiveness of the lower risk decision rule strategies compared 16 
with no therapy, with the 12.5% decision rule strategy yielding an 17 
ICER of £11,129/QALY gained. The age profile of patients made a 18 
difference to results. Allowing for a patient population to be aged 60 19 
and above only (higher bleeding risk on anticoagulation) revealed 20 
the 22.5% threshold option and above to be a cost-effective option, 21 
with all other options not cost-effective. Likewise, model results 22 
were sensitive to a patient’s index VTE event type. All decision rule 23 
strategies of 10% and above were cost effective when the patients’ 24 
index event was a PE reflecting the high risk nature of such index 25 
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events. In contrast, the 25% threshold was the only cost effective 1 
options when the patients’ index event was a DVT. 2 
Adjusting the lag time had little effect on the cost-effectiveness of 3 
the results except for the 15% decision rule; this was now cost-4 
effective when the lag time was increased from 20 to 40 days. 5 
Having a male-only cohort meant the lowest threshold to be cost-6 
effective is the 12.5% while a female-only cohort restricted the 7 
lowest threshold to be cost-effective to 15%.  8 
Discussion 9 
Principal findings 10 
The economic evaluation assessed the cost-effectiveness of utilising 11 
a decision rule for the resumption of anticoagulation therapy in 12 
patients with a first unprovoked VTE. The base-case results indicate 13 
that treating patients with a predicted one year VTE risk of 17.5% 14 
and above with warfarin could be cost-effective compared to the 15 
next most effective option. These VTE risk cut-off points for 16 
treatment were much higher than what is considered acceptable in 17 
the literature.[21]  18 
However, PSA results suggest great caution must be applied when 19 
considering the base case results. Above 25% of the iterations 20 
showed less QALYs in the restarting anticoagulation decision rule 21 
strategies compared to the not restarting anticoagulation therapy 22 
strategy (“treat no-one”); the 17.5% decision rule was  the optimal 23 
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option in less than half the iterations when compared to the higher 1 
VTE risk thresholds in the CEACs. 2 
Quality of life on treatment and mortality risk were important 3 
determinants in the cost-effectiveness results. Incorporating a 4 
greater disutility on warfarin therapy changes the results with only 5 
the 22.5% and 25% VTE risk threshold options remaining cost-6 
effective. Meanwhile, a small change in the proportion of PEs that 7 
result in death makes restarting anticoagulation therapy at 12.5% 8 
even more cost-effective. 9 
Focusing on different subcategories of patients also changes the 10 
base-case results. Sensitivity analyses suggest that all index PE 11 
patients with a predicted VTE recurrence risk of 10% and above 12 
should be treated with lifelong anticoagulation therapy, likely 13 
because these patients were assumed to have a higher risk of a 14 
recurrent VTE that would be a PE. Conversely, for index DVT 15 
patients, the only restart anticoagulation option favoured on cost-16 
effectiveness grounds is a one year recurrent VTE risk of 25% or 17 
higher. The impact of higher bleeding risks from anticoagulation 18 
therapy in the older patient population aged sixty and above was 19 
not offset by the reduced risk of recurrent VTE at the lower risk 20 
thresholds strategies. 21 
Strengths and weaknesses of the analysis 22 
This is the first economic evaluation to consider using a decision rule 23 
to weigh up the advantages and disadvantages of resuming 24 
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anticoagulation treatment in unprovoked VTE patients.  A key 1 
strength of the analysis is the use of an individual patient simulation 2 
which allows a personalised risk prediction for hypothetical patients 3 
with characteristics drawn from real patient data. This was 4 
preferable to the more common cohort model with a homogenous 5 
set of characteristics as the model results were more representative 6 
of a realistic patient population.  The modelling method lessened 7 
the need for a multitude of separate health states as the Markovian 8 
lack of memory assumption encountered in cohort models was 9 
overcome by tracker variables. 10 
Several simplifying assumptions were needed. The prognostic model 11 
used to calculate individual risk predictions was applied at 30 days 12 
post cessation of anticoagulation therapy which is not clinically ideal 13 
as some patients will have recurrence in these thirty days. This was 14 
due to D-dimer measurements being included within the prognostic 15 
model as an important predictor improving model discrimination, 16 
and so stratification of patients into high and low risk groups (as in 17 
the decision rule examined here).[12] D-dimer measurements were 18 
only available post cessation of therapy in the original dataset, 19 
however there is much interest and potential benefit in the use of 20 
D-dimer measurements on therapy as a predictor.[22] Indeed this 21 
would allow immediate treatment decisions to be made before 22 
cessation of therapy, potentially negating the small number of 23 
possible recurrent events in the 30 day window from cessation of 24 
therapy to use of the decision rule evaluated here. The model does 25 
not include pulmonary hypertension which could be considered a 26 
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further limitation and its inclusion may lower the risk threshold for 1 
treatment.  2 
In the absence of data, constant VTE recurrence risks were used 3 
beyond three years, after a subsequent VTE and on treatment. In 4 
practice, recurrent VTE risk is likely to vary by patient characteristics. 5 
Additionally, the use of the prognostic model for the economic 6 
analysis implicitly assumes that the risk prediction tool is perfectly 7 
accurate. However, there will be a degree of error between 8 
predictions and reality. For example, the prognostic model was 9 
derived from patient level trial data and there is an inherent 10 
selectivity of patients in trials (e.g. fewer co-morbidities).In addition, 11 
the course of action on the resumption and cessation of 12 
anticoagulation after a major bleeding event may differ between 13 
patients. In truth, some patients may continue with their 14 
anticoagulation therapy after a major bleed while others who 15 
subsequently go on to suffer a VTE may not restart anticoagulation 16 
due to their high bleeding risk.  17 
Only considering a health care perspective was considered in this 18 
model, in line with UK national guidance, where threshold values of 19 
cost-effectiveness are available (£20,000-£30,000 per QALY).[19] 20 
Cost-effectiveness may differ when using the societal perspective, 21 
but it would be difficult to determine in what direction. Whilst 22 
patient-incurred costs would be higher with prolonged treatment 23 
with lifelong anticoagulation due to visits for INR tests, productivity 24 
losses may be higher in where there is a higher risk of clinical events 25 
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such as DVT, PE and bleeds, or if anticoagulation is required due to a 1 
further thrombotic event. 2 
Future research 3 
The sensitivity analyses have shown the large uncertainty underlying 4 
many of the parameters and their effect on results. Thus, there is a 5 
need for robust long-term data on the risk of recurrent VTE in 6 
unprovoked index VTE patients. The decision rule aims to balance 7 
the risks of recurrence and bleeding, and as such accurate bleeding 8 
risk data is required for the unprovoked population. It is likely that 9 
similar to the risk of VTE recurrence, the bleeding risk of individuals 10 
is highly heterogeneous, and as such a prognostic model similar to 11 
that used for predicting patients VTE recurrence risk could be 12 
invaluable in improving the accuracy of the economic evaluation 13 
results.  Lastly, future research should aim to incorporate on therapy 14 
predictors such as D-dimer in prognostic models to provide more 15 
timely risk predictions useful for clinical practice. 16 
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Table I- Model Parameters 1 
Parameter 
(distribution type) 
Estimate 
(distribution parameters) 
Source 
Clinical Parameters - - 
Annual risk of recurrent VTE off 
therapy (fixed) 
Prognostic model 
equation (see Appendix 
Table I) 
[12] 
Short term 6 month risk of 
recurrent VTE on anticoagulation 
therapy (beta) 
2.1% (=27, =1239) [23] 
Long-term annual risk of VTE 
recurrence beyond 6 months on 
therapy (beta) 
1.3% (=1, =78) [24] 
Long-term annual risk of VTE 
recurrence beyond 3 years off 
therapy(beta) 
 
5.0% (=5, =95) 
 
 
[15] 
 
Annual risk of further VTE off 
therapy after previous recurrent 
VTE (beta) 
Off therapy 
On therapy 
 
 
 
12.0% (=11, =81) 
5.0% (=5, =95) 
 
 
[16] 
Probability a recurrent VTE is a PE 
by index event (beta) 
Index event DVT 
Index event PE 
 
 
0.15 (=15, =88) 
0.52 (=30, =28) 
 
 
[13] 
Probability of death from PE in 
the  first month (beta) 
0.2 (=2, =8) Clinical consensus 
Proportion of recurrent VTEs 
resulting in severe PTS (beta) 
1.1% (=4, =345) [25] 
Annual risk of major bleed by age 
group (beta)                                 
  Not on therapy 
 
On therapy  
<65 
65-74 
75+ 
 
 
0.45%(=25,=5593) 
 
 
2.43% (=23, = 929) 
3.25% (=86, =2554) 
4.37% (=106, =2324) 
 
 
[26] 
 
 
[27]  
Split of major bleeds by bleed 
type (dirichlet) 
Gastrointestinal bleed 
Intracranial bleed 
Other major bleed 
 
 
 
36.5% 
17.9%  
45.6%  
(α1;α2;α3) =  
(499;245;622) 
 
[28]  
Risk of death from major bleed 
(first month) (beta) 
Gastrointestinal bleed 
Intracranial bleed 
Other major bleed 
 
 
18.4% (=92, =407) 
32.2% (=79, =166) 
10.5% (=65, =557) 
 
[28] 
Standardised mortality ratio for 
after an intracranial bleed 
(Lognormal)
1 
2.2 (95% CI 2.0-2.4) [29] 
Unit costs - - 
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Pulmonary Embolism (fixed) £1,519 [30]  
Distal Deep Vein Thrombosis 
(fixed) 
£732 [30] 
Proximal Deep Vein Thrombosis 
(fixed) 
£732 [30] 
12 months warfarin monitoring 
(fixed) 
£337 [31] 
Warfarin (4mg per day, 12 
months) (fixed) 
£22 [32] 
Gastrointestinal bleed (fixed) £1,092 [30] 
Other major bleed (fixed) £1,092 Assumed same as 
GI Bleed 
Intracranial bleed: acute cost 
(gamma) 
£8,350 
(=31.0, =269.4)
2
 
[33]  
Intracranial bleed: annual cost 
(fixed) 
£1,300 [33] 
D-Dimer test £26 [34] 
1. A 95% confidence interval is assumed to be ±0.2 of the mean. 
2. 
 is the shape parameter and  is the scale parameter 
VTE= Venous Thromboembolism, PTS=Post Thrombotic Syndrome, PE= Pulmonary 
Embolism 
 1 
Table II- Utility Values for Health States 2 
Health 
state/ 
clinical 
event 
Median Utility 
value 
(Inter-Quartile 
Range) 
Beta 
distribution 
Duration 
of Disutility 
Source 
DVT 0.84 (0.64-
0.98) 
=2.0, 
=0.6 
1 month [35]  
PE 0.63 (0.36-
0.86) 
=1.2, 
=0.8 
1 month [35]  
Non-fatal  
intracranial 
bleed 
0.33 (0.14-
0.53) 
=1.2, 
=2.1 
Permanent [35]  
GI Bleed 0.65 (0.49-
0.86) 
=1.2, 
=0.8 
2 weeks [35]  
Other 
Bleeds 
0.65 (0.49-
0.86) 
=1.2, 
=0.8 
2 weeks Assumed same as GI 
Bleeds 
Severe PTS 0.82 (0.66-
0.97) 
=3.0, 
=0.9 
Permanent [35] 
Warfarin 0.997 (0.953-
1.0)
1 
=16.4, 
=0.3 
Treatment 
length 
[36] 
1. 
10
th
 and 90
th
 percentile reported instead of Inter-Quartile Range (IQR) 
GI Bleed= Gastrointestinal Bleed, DVT= Deep Vein Thrombosis, PTS=Post 
Thrombotic Syndrome 
 3 
 4 
 5 
 6 
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Table III - Cost-effectiveness of using each decision rule sorted by increasing 1 
effectiveness (Lifetime time horizon) 2 
Strategy Mean cost (£) Mean QALYs ICER (Cost/QALY) 
(£)  
Treat all 5882 10.4134 Dominated  
Decision rule: 1% 5791 10.4223 Dominated  
Decision rule: 3% 5468 10.4522 Dominated  
Decision rule: 5% 5006 10.4897 Dominated  
Treat No one 3284 10.5160 - 
Decision rule: 7.5% 4411 10.5309 Dominated  
Decision rule: 25% 3324 10.5361 1983 
Decision rule: 22.5% 3347 10.5404 5360 
Decision rule: 20%  3385 10.5427 
Extended 
domination  
Decision rule: 17.5% 3443 10.5468 14980 
Decision rule: 15%  3541 10.5511 22708 
Decision rule: 10%  3962 10.5534 Dominated 
Decision rule: 12.5% 3703 10.5542 53178 
ICER= Incremental Cost-Effectiveness Ratio, QALY= Quality-Adjusted Life Year, VTE= 
Venous Thromboembolism 
Decision rule strategies based on whether to restart warfarin therapy according to a 
patient’s predicted 1 year risk of a VTE recurrence. Strategies are compared with 
the next best non-dominated option. 
 3 
 4 
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Table IV- Sensitivity Analysis Scenarios 
Strategy Mean 
cost 
(£) 
Mean 
QALYs 
ICER 
(Cost/QALY) 
(£)  
Strategy Mean 
cost (£) 
Mean 
QALYs 
ICER 
(Cost/QALY) 
(£) 
3 year time horizon    Male only patients    
Treat No-one 385 2.2066 - Treat No-one 3520 10.6271 - 
Decision Rule: 25% 395 2.2085 5108 Decision Rule: 25% 3580 10.6666 1509 
Decision Rule: 22.5% 402 2.2090 14520 Decision Rule: 22.5% 3613 10.6764 3378 
Decision Rule: 17.5% 430 2.2097 40182 Decision Rule: 17.5% 3743 10.7019 5085 
Decision Rule: 12.5% 510 2.2107 82797 Decision Rule: 12.5% 4109 10.7352 10975 
    Decision Rule: 10% 4455 10.7471 29022 
        
Higher risk of death 
from PE 
   
Female only patients    
Treat No-one 3163 10.3430 - Treat No-one 2842 9.8863 - 
Decision Rule: 25% 3208 10.3725 1507 Decision Rule: 25% 2856 9.8906 3217 
Decision Rule: 22.5% 3234 10.3802 3447 Decision Rule: 20% 2881 9.8963 4403 
Decision Rule: 17.5% 3332 10.3958 6250 Decision Rule: 17.5% 2906 9.9001 6746 
Decision Rule: 15% 3434 10.4088 7882 Decision Rule: 15% 2948 9.9058 7272 
Decision Rule: 12.5% 3602 10.4238 11129 Decision Rule: 10% 3182 9.9144 27337 
Decision Rule: 10% 3868 10.4327 29850 Decision Rule: 7.5% 3510 9.9176 102125 
        
All patients aged ≥60 
years  
   Lag d-dimer time of 
20 days 
   
Treat No-one 2412 8.3657 - Treat No-one 3376 10.4989 - 
Decision Rule: 25% 2443 8.3771 2767 Decision Rule: 25% 3427 10.5245 1994 
Decision Rule: 22.5% 2462 8.3783 15460 Decision Rule: 17.5% 3575 10.5370 11842 
Decision Rule: 20% 2487 8.3794 22315 Decision Rule: 15% 3690 10.5423 21728 
Decision Rule: 17.5% 2531 8.3805 42386 Decision Rule: 12.5% 3883 10.5459 53213 
Decision Rule: 15% 2601 8.3807 253213     
        
All patients with 
index PE event 
   Lag d-dimer time of 
40 days 
   
No treat 3309 10.1416 - Treat No-one 3227 10.5295 - 
Decision Rule: 25% 3356 10.1842 1105 Decision Rule: 25% 3261 10.5459 2073 
Decision Rule: 22.5% 3384 10.1975 2094 Decision Rule: 22.5% 3280 10.5492 5701 
Decision Rule: 20% 3429 10.2102 3561 Decision Rule: 20% 3314 10.5519 12669 
Decision Rule: 17.5% 3499 10.2229 5479 Decision Rule: 15% 3447 10.5594 17634 
Decision Rule: 15% 3614 10.2403 6634 Decision Rule: 12.5% 3589 10.5619 58581 
Decision Rule: 12.5% 3799 10.2639 7836     
Decision Rule: 10% 4089 10.2868 12633     
Decision Rule: 7.5% 4589 10.3000 38079     
        
All patients with 
index DVT event 
   Higher warfarin 
disutility   
 
Treat No-one 3165 10.7310  Treat No-one 3284 10.3319  
Decision Rule: 25% 3197 10.7361 6277 Decision Rule: 25% 3324 10.3451 3008 
Decision Rule: 22.5% 3213 10.7365 50891 Decision Rule: 22.5% 3347 10.3466 16217 
ICER= Incremental Cost-Effectiveness Ratio, QALY= Quality-Adjusted Life Year, PE= Pulmonary Embolism, DVT= Deep Vein 
Thrombosis 
Decision rule strategies based on whether to restart warfarin therapy according to a patient’s predicted 1 year risk of a VTE 
recurrence. Dominated strategies (more costly and less effective) are excluded from the table. 
 
